EUVIMEDEUVIMED entdecken
Open Access

Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells

Kevin Luk, Pengpeng Liu, Jing Zeng, Yetao Wang, Stacy A Maitland, Feston Idrizi, Karthikeyan Ponnienselvan, Sukanya Iyer, Lihua Julie Zhu, Jeremy Luban, Daniel E Bauer, Scot A Wolfe

GEN Biotechnology · 2022

DOI: 10.1089/genbio.2022.0003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift GEN Biotechnology, 2022. Verfasst von Kevin Luk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cell and Cancer Biology, Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Wor…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type V CRISPR–Cas12a systems are an attractive Cas9-alternative nuclease platform for specific genome-editing applications. However, previous studies demonstrate that there is a gap in overall activity between Cas12a and Cas9 in primary cells. Here we describe optimization to the nuclear localization signal (NLS) composition and architecture of Cas12a to facilitate highly efficient targeted mutagenesis in human transformed cell lines (HEK293T, Jurkat, and K562 cells) and primary cells (natural killer [NK] cells and CD34+ hematopoietic stem and progenitor cells [HSPCs]), regardless of Cas12a ortholog. Our 3xNLS Cas12a architecture resulted in the most robust editing platform. The improved editing activity of Cas12a in both NK cells and CD34+ HSPCs resulted in pronounced phenotypic changes associated with target gene editing. Lastly, we demonstrated that optimization of the NLS composition and architecture of Cas12a did not increase editing at potential off-target sites in HEK293T or CD34+ HSPCs. Our new Cas12a NLS variant provides an improved nuclease platform for therapeutic genome editing.

Autor:innen und Institutionen

  • Department of Molecular, Cell and Cancer Biology, Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, MA, USA.
  • Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
  • Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Pediatrics, Harvard Stem Cell Institute, Broad Institute of Harvard and MIT, Harvard Medical School, Boston, MA, USA.
  • Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
  • Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Jiangsu Key Laboratory of Mol…

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Luk, K., Liu, P., Zeng, J., Wang, Y., Maitland, S. A., Idrizi, F., Ponnienselvan, K., Iyer, S., Zhu, L. J., Luban, J., Bauer, D. E., & Wolfe, S. A. (2022). Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells. GEN Biotechnology. https://doi.org/10.1089/genbio.2022.0003

Vancouver

Luk K, Liu P, Zeng J, Wang Y, Maitland SA, Idrizi F, et al. Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells. GEN Biotechnology. 2022. doi:10.1089/genbio.2022.0003

BibTeX
@article{Luk2022,
  author = {Luk, Kevin and Liu, Pengpeng and Zeng, Jing and Wang, Yetao and Maitland, Stacy A and Idrizi, Feston and Ponnienselvan, Karthikeyan and Iyer, Sukanya and Zhu, Lihua Julie and Luban, Jeremy and Bauer, Daniel E and Wolfe, Scot A},
  title = {Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells},
  journal = {GEN Biotechnology},
  year = {2022},
  doi = {10.1089/genbio.2022.0003}
}
Kostenlos starten →